The aims of this retrospective study were to determine the incidence of BCR‐ABL KD mutations according to patient's baseline characteristics and TKI failure situations at the time of mutation analysis (using Sanger sequencing) and to analyze the outcome of CML patients with and without mutations. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.